Latest news with #Coloplast
Yahoo
a day ago
- Business
- Yahoo
Coloplast AS (CLPBF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Challenges
This article first appeared on GuruFocus. Organic Revenue Growth: 7% for the third quarter. EBIT Margin Before Special Items: 28% in the third quarter. Adjusted Return on Invested Capital: 15%, on par with last year. Ostomy Care Organic Growth: 6% for the first nine months. Continence Care Organic Growth: 8% for the first nine months. Voice and Respiratory Care Organic Growth: 9% for the first nine months. Advanced Wound Care Organic Growth: 9% for the first nine months. Kerecis Growth: 26% for the first nine months. Interventional Urology Organic Growth: 1% for the first nine months. Gross Margin: 68% for the first nine months. Operating Profit Before Special Items: DKK 5.7 billion for the first nine months. Net Profit Before Special Items: DKK 3.8 billion for the first nine months. Operating Cash Flow: DKK 4.4 billion for the first nine months. Free Cash Flow: DKK 3.5 billion for the first nine months. CapEx: 5% of sales for the first nine months. Warning! GuruFocus has detected 4 Warning Signs with CLPBF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Coloplast AS (CLPBF) reported a 7% organic growth for the third quarter, driven by broad-based growth across its Chronic Care businesses. The company has reorganized its structure into two business units, Chronic Care and Acute Care, to better address market dynamics and customer needs. Coloplast AS (CLPBF) is focusing on innovation, with plans to bring new products to market faster and enhance R&D capabilities. The company has maintained a stable EBIT margin of 27% to 28% before special items, demonstrating effective cost management. Kerecis, a part of the Advanced Wound Care segment, showed strong growth of 26% in the first nine months, indicating robust demand for its products. Negative Points The Advanced Wound Care business fell short of expectations due to product returns in China and lower-than-expected growth for Kerecis. The US Centers for Medicare and Medicaid Services proposed rules that could impact Coloplast AS (CLPBF)'s Chronic Care business, introducing uncertainty about future financial impacts. The company faced a negative impact from foreign exchange rates, which reduced reported revenue by approximately 1%. Coloplast AS (CLPBF) experienced a product recall in China, leading to a significant negative financial impact in the third quarter. The Bladder Health and Surgery segment continued to detract from growth, with uncertainty around the timeline for full recovery. Q & A Highlights Q: Lars, we've seen product recalls and execution issues. What steps are you taking to prevent future recalls? A: Lars Rasmussen, Interim CEO: The recall of urological products was due to a sterilization barrier breach, a common issue in the industry. The situation in China with Biatain foam products is different; it's a technical specification issue unique to China, not a quality problem. We're discussing this with the market and working on substitute products, but it's a slow process. Q: Can you elaborate on the INTIBIA filing and your confidence in regulatory acceptance? A: Anders Lonning-Skovgaard, CFO: We are on track with the INTIBIA launch and expect to get it through the FDA process in the US. We anticipate launching in the first part of the next strategic period. Q: Regarding Kerecis, how was growth in non-physician office settings, and what are the incentives for physicians to use higher-priced products? A: Anders Lonning-Skovgaard, CFO: In Q3, high-priced products reentered the market due to an LCD delay, impacting sales. We expect a bounce back in Q4. The new skin substitute price is being discussed and expected to be implemented in January 2026. Q: On the competitive bidding proposal, can you provide more details on the potential impact on US Chronic Care sales? A: Lars Rasmussen, Interim CEO: It's difficult to estimate the impact, but competitive bidding on specialized products like Ostomy Care seems illogical due to the complexity and variety of SKUs. We estimate around 50% of our US sales are Medicare-related. Q: Can you explain the rationale behind establishing R&D franchises within Chronic Care? A: Lars Rasmussen, Interim CEO: Innovation is crucial, and we aim to bring products to market faster and derive more value from them. This change elevates R&D to the executive level to ensure close collaboration with manufacturing, enhancing both innovation and profitability. For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Yahoo
2 days ago
- Business
- Yahoo
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to Executive Leadership Team
Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, senior leaders from across the Coloplast Group have worked together to finalise the new Coloplast Group strategy, which will be communicated internally and externally in early September following approval by the Board of Directors. 'Our new strategy is centered around our customers. We will create and deliver the best customer experience for our users, patients and clinicians across our offering of products, support and services. Our ambition is to set the standard of care, to lead the market and to win!' says Lars Rasmussen, interim CEO of Coloplast. 'To deliver value for our customers, shareholders and more, we must evolve. That means putting the customer at the centre of everything we do. It also means delivering a step change in innovation to solidify our position as the innovation leader in our industry,' says Lars. During the current strategy period, the Coloplast Group has expanded with the addition of Atos Medical and Kerecis. Effective immediately, the company will organise its businesses into two distinct business units: Chronic Care and Acute Care. This structure allows the company to respect the differences in market dynamics, customer needs, patient pathways and business models, and it creates the needed structure to execute on the company's 2030 strategy. Changes to Chronic CareEffective immediately, a new Chronic Care Commercial business unit is being established. This will include the existing Chronic Care sales regions as well as relevant Chronic Care commercial functions. Given the chronic nature of most patients served by Atos Medical, the Voice & Respiratory Care business, Atos will also become part of the new Chronic Care Commercial business unit. To deliver a step change in innovation and bring new products faster to market, a stand-alone Chronic Care R&D function is also being established. 'As we are making significant changes to the Chronic Care setup, the Board and Executive Vice President Nicolai Buhl have mutually agreed that Nicolai will leave Coloplast. Nicolai has achieved great things in his time with Coloplast as a senior leader within Wound Care as well as Chronic Care. On behalf of the Board and the ELT, I want to thank Nicolai for his dedication and leadership,' says Lars. Caroline Vagner Rosenstand will take on the role as Executive Vice President of Chronic Care Commercial. 'Caroline is an experienced leader with a great track record of building followership, defining and executing on commercial strategies and delivering results,' says Lars. On November 1st, Rasmus Just will step into the role of Executive Vice President of Chronic Care R&D. Rasmus Just brings valuable experience from his five years at Coloplast, where he held several leadership roles within innovation, before continuing his career for the past 3 years in Device R&D at Novo Nordisk. 'Rasmus is an experienced R&D leader with a strong technology and business focus, and we are happy to welcome him back to Coloplast,' says Lars. Introducing Acute CareThe new Acute Care business unit includes Interventional Urology (IU), Advanced Wound Dressings (AWD) and Kerecis. These treatment areas are characterised by premium products like Coloplast's penile implants, the Kerecis fish skin portfolio and our wound dressings. Most of these products and technologies are used in specialised private clinics or in the hospital setting, where innovation and clinical outcomes are critical. Effective immediately, the AWD and Kerecis commercial organisations are being merged into a new Wound & Tissue Repair organisation within Acute Care. The goal is to become an innovation leader in this area and to create a strong global footprint by merging these two complementary businesses. Wound & Tissue Repair will be led by Executive Vice President Fertram Sigurjonsson. 'With Kerecis, Fertram has built a company with strong innovation capability and growth potential based on a unique technology. Bringing these capabilities together in a new Wound & Tissue Repair unit represents a significant milestone for our AWD and Kerecis businesses,' says Lars. There are no changes to the IU business, which will continue under the leadership of Executive Vice President Tommy Johns. 'I would like to congratulate Caroline, Fertram and Rasmus on their new roles,' ends Lars. The new ELT Lars Rasmussen, interim CEO Anders Lonning-Skovgaard, EVP & CFO Allan Rasmussen, EVP Global Operations Dorthe Rønnau, EVP People & Culture Caroline Vagner Rosenstand, EVP Chronic Care Commercial Rasmus Just, EVP Chronic Care R&D (start date 1 November) Fertram Sigurjonsson, EVP Wound & Tissue Repair Tommy Johns, EVP Interventional Urology Lars Rasmussen, interim President and CEO, and Anders Lonning-Skovgaard, Executive Vice President and CFO, constitute the management registered with the Danish Business Authority. ContactsPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@ Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 2458Email: dkadim@ Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 3266Email: dkkhu@ Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 2981Email: dksdk@ This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound and Skin Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, 05_2025_Coloplast_announces_changes_to_ELTSign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Coloplast A/S - Interim Financial Report, 9M 2024/25
2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin1,2 was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin1 was 27%, on par with last year2. Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. "We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register hereAccess the conference call webcast directly here: Coloplast - 9M 2024/25 conference call For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@ Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: dkkhu@ Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981Email: dksdk@ Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@ AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917 This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_releaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 days ago
- Business
- Business Upturn
Coloplast A/S – Interim Financial Report, 9M 2024/25
By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
08-08-2025
- Business
- Yahoo
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST
Tuesday, 19 August 2025 at 11.00 - 12.00h CESTIn connection with the publication of Coloplast's interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast's website approximately 1 hour before the conference webcast of the conference call will be available during and after the event. Coloplast will be represented by: Lars Rasmussen - Interim CEOAnders Lonning-Skovgaard - Executive Vice President, CFOAleksandra Dimovska - Vice President, Investor RelationsKristine Husted Munk - Senior Manager, Investor RelationsSimone Dyrby Helvind - Senior Manager, Investor Relations WebcastFor participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below: Dial-in detailsTo actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details. For more information, please contact: Aleksandra Dimovska - Vice President, Investor RelationsTel.: +45 4911 1800 / direct: +45 4911 2458. E-mail: dkadim@ Kristine Husted Munk - Senior Manager, Investor RelationsTel.: +45 4911 1800 / direct: +45 4911 3266. E-mail: dkkhu@ Simone Dyrby Helvind - Senior Manager, Investor RelationsTel.: +45 4911 1800 / direct: +45 4911 2981. E-mail: dksdk@ Julie Sommer Müggler - Coordinator & PA, Investor RelationsTel.: +45 4911 1800 / direct: +45 4911 3161. E-mail: dkjusm@ Coloplast will be available on individual phone lines after the conference call for further questions. Attachment Invitation to Coloplast 9M 2024-25 conference call on 19 August 2025Sign in to access your portfolio
